BOSTON, March 19, 2026 (GLOBE NEWSWIRE)-- Damora Therapeutics, Inc. (formerly Galecto, Inc.) (“Damora” or the “Company”) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care ...
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in ...
BOSTON, March 23, 2026 (GLOBE NEWSWIRE)-- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced ...
Investing.com -- Damora Therapeutics Inc (NASDAQ:DMRA) shares jumped 15.5% Monday following the announcement of Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026.
-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results